Sarah Kathryn Rouan
Known title: DirectorCIK: 0001761366
Sarah Kathryn Rouan's purchase track record
Sarah Kathryn Rouan has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/31/2025 | VKTX | $30K | +9.7% | +6.9% | +18.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VKTX | ▲ Buy | Grant | 3,150 | $0 | 1/2/2026 | View on chart |
| VKTX | ▲ Buy | Open Market | 1,240 | $30K | 3/31/2025 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 11,000 | $54K | 10/25/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 11,000 | $890K | 10/25/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 25,000 | $208K | 2/8/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 25,000 | $701K | 2/8/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 30,000 | $250K | 1/19/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 30,000 | $692K | 1/19/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Viking Therapeutics Launches New Oral Obesity Study
Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.
Viking Therapeutics Launches New Oral Obesity Study. Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.